SCHEMBL15814005

SCHEMBL15814005

Cc1cc(Cl)ccc1C1SCC(=O)Nc2c1c(O)nn2C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
GAA P10253 1/20 0.45
TP53 P04637 4/20 0.41
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
TSHR P16473 2/20 0.39
ALOX15 P16050 1/20 0.39
CASP1 P29466 1/20 0.39
RECQL P46063 1/20 0.39
SLC8B1 Q6J4K2 1/20 0.39
HPGD P15428 4/20 0.37
PROKR1 Q8TCW9 4/20 0.37
CYP3A4 P08684 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NR1H4 Q96RI1 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15813572 0.89 MAPT (0.48) MAPTGAATP53CYP1A2CYP2C9
SCHEMBL15814040 0.82 MAPT (0.37) MAPTGAATP53CYP1A2CYP2C9
SCHEMBL15813807 0.82 PROKR1 (0.36) GAAPROKR1TAAR1MDM4MDM2
SCHEMBL15814148 0.81 MAPT (0.36) MAPTGAATP53CYP1A2CYP2C9
SCHEMBL15813716 0.81 TP53 (0.40) MAPTGAATP53CYP1A2CYP2C9
SCHEMBL15813813 0.81 MAPT (0.48) MAPTGAATP53CYP1A2CYP2C9
SCHEMBL15813492 0.80 MDM4 (0.36) MAPTGAATP53CYP1A2CYP2C9
SCHEMBL15813683 0.79 MAPT (0.40) MAPTGAATP53CYP1A2CYP2C9
SCHEMBL15813197 0.78 MAPT (0.42) MAPTGAATP53CYP1A2CYP2C9
SCHEMBL15813500 0.77 MAPT (0.43) MAPTGAATP53CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150592-B2 Heterocyclic nuclear hormone receptor modulators ABBVIE INC. (US) 2015-10-06 US disclosed
US-20140179676-A1 HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS ABBVIE INC. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179676-A1 HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS NR5A2, NR5A1, GPER1 MAPT 4520/4885GAA 4442/4885TP53 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.